SCHEMBL24024481

SCHEMBL24024481

N=C(N)c1ncn([C@@H]2OC(COP(=O)(O)O)[C@@H](O)[C@H]2O)n1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNP P00491 3/20 0.67
FBP1 P09467 2/20 0.55
ATIC P31939 2/20 0.55
LMNA P02545 3/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
ADORA1 P30542 2/20 0.55
ALDH1A1 P00352 1/20 0.55
GLA P06280 1/20 0.55
EIF4E P06730 1/20 0.55
CYP3A4 P08684 1/20 0.55
TOP1 P11387 1/20 0.55
TSHR P16473 1/20 0.55
THPO P40225 1/20 0.55
PMP22 Q01453 1/20 0.55
TAS1R3 Q7RTX0 3/20 0.51
TAS1R1 Q7RTX1 3/20 0.51
DNPH1 O43598 1/20 0.51
PRKAB2 O43741 1/20 0.51
TRPM2 O94759 1/20 0.51
LDHA P00338 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13780801 1.00 PNP (0.67) PNPFBP1ATICLMNASMN1; SMN2
SCHEMBL24024489 1.00 PNP (0.67) PNPFBP1ATICLMNASMN1; SMN2
Ribavirin Monophosphate SCHEMBL1508870 0.90 LMNA (0.69) PNPFBP1ATICLMNASMN1; SMN2
Ribavirin Monophosphate SCHEMBL11202379 0.90 LMNA (0.69) PNPFBP1ATICLMNASMN1; SMN2
Ribavirin Monophosphate SCHEMBL10882076 0.90 LMNA (0.69) PNPFBP1ATICLMNASMN1; SMN2
Ribavirin Monophosphate SCHEMBL12727825 0.90 LMNA (0.69) PNPFBP1ATICLMNASMN1; SMN2
Ribavirin Monophosphate SCHEMBL11654617 0.89 LMNA (0.67) PNPFBP1ATICLMNASMN1; SMN2
SCHEMBL15788463 0.84 PNP (0.73) PNPFBP1ATICLMNASMN1; SMN2
SCHEMBL13606969 0.83 PNP (0.69) PNPFBP1ATICLMNASMN1; SMN2
SCHEMBL12300348 0.82 PNP (0.70) PNPFBP1ATICLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210353660-A1 Pre-Activated Nucleoside IMPDH Inhibitors As Anti-Infective Drugs OCTAGON THERAPEUTICS INC. (US) 2021-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210353660-A1 Pre-Activated Nucleoside IMPDH Inhibitors As Anti-Infective Drugs IMPDH1, IMPDH2, PNP PNP 3/4885FBP1 527/4885ATIC 86/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.